NasdaqGS:IBRXBiotechs
Why ImmunityBio (IBRX) Is Up 8.3% After Promising ANKTIVA Data in Advanced Lung Cancer
ImmunityBio announced new findings from its Phase 2 QUILT-3.055 study, revealing that ANKTIVA reversed lymphopenia and was associated with significantly longer median overall survival in checkpoint inhibitor-resistant advanced non-small cell lung cancer patients, as presented at the IASLC 2025 World Conference on Lung Cancer.
These results spotlight ANKTIVA as the first therapy specifically under investigation for reversing cancer-related lymphopenia, targeting an unmet need for patients...